1 / 9

Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity

Featured Article :. Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity. Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D., Carlos A. Schiavon, M.D., João E. Salles, M.D., Bernardo L. Wajchenberg, M.D., David E. Cummings, M.D. Diabetes Care

masako
Télécharger la présentation

Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D., Carlos A. Schiavon, M.D., João E. Salles, M.D., Bernardo L. Wajchenberg, M.D., David E. Cummings, M.D. Diabetes Care Volume 35: 1420-1428 July, 2012

  2. Study Objectives • Roux-en-Y gastric bypass (RYGB) ameliorates type 2 diabetes in severely obese patients through mechanisms beyond just weight loss, and it may benefit less obese diabetic patients • Study determined the long-term impact of RYGB on patients with diabetes and only class I obesity (BMI 30–35 kg/m2 ) Cohen R et al. Diabetes Care 2012;35:1420-1428

  3. Study Design & Methods • Sixty-six consecutively selected diabetic patients with BMI 30–35 kg/m2 underwent RYGB in a tertiary-care hospital and were prospectively studied for up to 6 years (median 5 years [range 1–6]), with 100% follow-up • Main outcome measures were safety and the percentage of patients experiencing diabetes remission (HbA1c < 6.5% without diabetes medication) Cohen R et al. Diabetes Care 2012;35:1420-1428

  4. Cohen R et al. Diabetes Care 2012;35:1420-1428

  5. Cohen R et al. Diabetes Care 2012;35:1420-1428

  6. Cohen R et al. Diabetes Care 2012;35:1420-1428

  7. Cohen R et al. Diabetes Care 2012;35:1420-1428

  8. Cohen R et al. Diabetes Care 2012;35:1420-1428

  9. Conclusions • Largest, longest-term study to date examining RYGB for diabetic patients without severe obesity • RYGB safely and effectively ameliorated diabetes and associated comorbidities, reducing cardiovascular risk, in patients with a BMI of only 30–35 kg/m2 Cohen R et al. Diabetes Care 2012;35:1420-1428

More Related